Member Info for notaflipper

https://uk.investing.com/news/commodities-news/oil-inventories-rose-by-42m-barrels-last-week-api-2252621

As someone mentioned before though stocks have risen more than expected in the last week due to economic slowdown, the WTI future has only slipped by 0.3%.

Positive news of BA trial. Hopefully it point to quarantine free travel by end of December which should massively increase aviation activity

seems to have been found in the back @ 149.645.
Think general market caution and news of potential hurdles to Air Europa purchase was taken advantage. Should rise going into the afternoon. Looking at the WTI and Brent futures the expectancy is for demand to increase so bar further financing concerns it looks like a Long Hold.

https://www.yourgene-health.com/about/the-y-series/your-comment/87-the-y-series/your-comment/1725-covid-19-vaccines-and-the-continued-role-of-testing

And SP is storming ahead to potential break out.
Surely must be something more in this TU than normal? I mean the Q3 update was just in early Oct so cannot take this long to trot out a monthly update.
False hope or leak or pricing in news and sell on release? Answers on a postcard please.

Any change in expectations from IR whether an Trading Update RNS is still expected this month?
SP seems quite healthy in the back regardless of whether it comes or not, so do not think it will effect the upward trend if this doesn't come. Just a pain to keep on checking each morning.

Hoping the slight delay in providing a trading update means that there still hope of getting a nice surprise. GLA for next week.

when this moves, it moves :-)
The revenue on new model with Covid-19 impact in the 9th Nov had a 25% impairment due to COVID. Hopefully the vaccination news means that this is overtly conservative and will be revised in the next few weeks.

Think we need to look forward to the good news of reopening of international markets were affected by the enforced lockdowns, which inhibited cross-border shipments and in-country non-COVID-19 testing, especially in Japan and India. The Trading Update did specifically mention the US and Japan. This article highlights that take up for these diagnostic products is significantly boosted in countries where reimbursements is provided by health care insurance or central governments. That is the reason why the reimbursement announcements in France and Wales were so significant.

Although the links shared do not specifically mention YourGene, PIs can note that this commercial strategy has been referenced by the Company. The 21 Sep RNS brought to Investors attention the appointment of Immuno-Biological Laboratories Inc (‘IBL-America’) as the non-exclusive distributor for several PCR (‘polymerase chain reaction’) tests across Yourgene’s reproductive health and oncology portfolios in the US.

Investors here are still awaiting the IONA Nx Commercial roll-out strategy which was delayed by COVID despite the opening of the Florida office in the US. However the Sep 21 RNS does explain the commercial roll-out of Yourgene’s DPYD products will initially be sold as Research Use Only (‘RUO’) to the research sector and to CLIA-certified laboratories for in-house validation prior to clinical use, with the potential for full FDA registration later depending on customer demand. Suspect this will be the same approach for the IONA Nx.

This I suspect will still be the same commercial roll-out strategy expected of IONA-Nx. However would agree that PIs who waited years for the IONA Illumina NIPT to be developed, then CE-IVD accredited should not have to wait many months to know at least what the commercial potential is. I have written my strongly worded e-mail, suggest you too. What is constantly failed to be appreciated is that Thermo Fisher has a 9% stake in YourGene Health and Illumina also has a vested interest (despite having a rival VerifiSeq test) to see the Company's sales increase as this benefits their sequencer sales. Similar to an App and a Mobile phone, with these two companies representing Samsung and Apple respectively in their IP approach and market dominance.

I think some perspective may be missing here following the fall-out from the Half Year Trading Update where it was the results were less than expectations. This now was a couple of weeks ago and we move on. Looking forward the sp is at the bottom of its normal trading range with a potential upside to 22p to 24p range in the next 4-6 months without any significant news. With the sp below the level of recent Director purchases, option awards and placing this negativity is now looking overdone.

All the best to all LTHs.

Over 75p in the back. Hope it holds and finishes over. Natural momentum seems to be building here and even with a half decent TU I suspect we would be over 80p by next week. Seems amazing to think that the sp was higher over the summer with less good news. Hopefully when the TU lands, it will be a cracker and there will be some decent re-rate following

Didn't someone here say they spoke to IR and it was coming today?

Agreed the dips were to allow IIs in. We'll probably be get a few Holding RNS. It's actually great that PIs are getting in at the same level as the big boys for a change. This nice steady rise is great in comparison to the volatility of some recovery or COVID stocks where there's often no logic to an intra-day swing of 50% on the sp. We should be touching 100p come Xmas with no nasty surprises.

https://www.dailymail.co.uk/news/article-8933799/Volunteers-given-Pfizers-breakthrough-Covid-vaccine-compare-jabs-effects-severe-hangover.html

Yes and no. There was a rumour that a vaccine, the efficacy was better than expected.
The Presidency was called on the weekend and the vaccine announced on the Monday. Trump repeatedly said a vaccine would come this year whereas Biden scaremongered on COVID. The delay was costly to Trump and odd given that Fauci and the Pfizer CEO repeatedly would not back his claims. How the BBC didn't ask about the timing is also interesting and not apolitical.

After 2big blue days the MMs will mark this down on open to sweat those with weak hands and to trigger stop orders.
If you are Long then remove your Stops.
Alternatively they will let it rise a bit, but again, there'll be a pull back to trigger stops.
Ultimately at some point the euphoria will end hence the shorts not being closed as we will have to return to the reality of the debt situation and lack of immediate revenue. MS purchase was on the 5th and notified today. So it will be interesting to see if a II takes the opportunity to de-risk in the next few days

Strange times.
With the recent Holding IIs, I am still more inclined that this is a period of consolidation and accumulation rather than the top ending of a bull run. However with the vaccine potential in Spring it does throw a lot of stuff up in the air. Hopefully there will be clear direction tomorrow. Good luck to all whom are still keeping their nerve!

With most COVID stocks loosing 30%-40% of the share price, YGEN's modest retrace points to underlying strength which hopefully should mean that the 16p floor is held in the coming days towards an upward channel of between 22p to 24p in the New Year. With the brokers keeping forecasts the same despite the disappointments in the Half Year trading update we are arguably trading at a discount to fair value. Key information that we are awaiting is the IONA Nx roll-out strategy following the geographical penetration into the US and Canada following the Coastal Genomics acquisition and the market potential for DYPD. In terms of the news of today, which we all have to be thankful for, I think we should be mindful that this will need to be a global roll-out even once the regulatory approval is given for the various mutant strains. Therefore realistically some testing will be required even post vaccination which would favour the more higher quality tests rather than the cheap and cheerful. YGEN has already stated that regulatory submissions for Clarigene are underway to access additional key regions and enable further geographical penetration. So even as the market diminishes in the UK we may see increasing sales globally which given that the current sales are modest should mean that the brokers' forecasts can still be maintained.

Looks like the numis note posted on the BB by @sjsrace has been deleted by the BB moderator

Painful holding, and reading, especially given the hype around the IC article. Poor volume and news flow up to this point. What is concerning me to add and average down is the statement that "it is unlikely that any further contracts won this year will result in significant additional revenue being recognised in 2020." Not sure how to balance this with the other statements that the "ARR run rate is expected to continue to grow and record a material increase by the end of 2020."

House broker Cenkos had previously suggested 2020 forecast revenue to increase by 10 per cent to $7.4m to deliver flat cash profit of $3m (£2.3m) suggesting operating costs of $4.4m. Looks like they will have enough cash with the recent placing however it could be one for the bottom drawer till next year at this rate.

Agreed.

There will have to be inevitably now a further re-rate following Shore Capital's greatly increased target price. We should not be surprised to expect a further trading update and a Holding RNS next week as well. The relative modest gain on Friday could be that there was some expectancy and continued market uncertainty acting as a drag. With the DOW Futures and Financials looking positive for next week this should be another blue week.

There may inevitably be some noises off on the bond rate terms being more generous than the last however as above this has been known by the market for some time and seemingly accepted. So I suspect these noises off will be by those looking for a better entry having not held or bought through the dip. Realistically it is expected that there will be refinancing for growth at far better rates next year or so when the markets are calmer. For now the differential gets rid of the great market uncertainty as a going concern which has supressed the sp for a limited increate in interest rates which is already covered by cash headroom.

Surely other IIs will follow Artemis now and we should see more holding RNS next week alongside a hopefully another trading update.